Business
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced an upcoming poster presentation that includes preclinical in vivo
About this update from Abcellera Biologics Inc.
[{"type":"text","content":" VANCOUVER, British Columbia--(BUSINESS WIRE)--\nAbCellera (Nasdaq: ABCL) today announced an upcoming poster presentation that includes preclinical in vivo data on its PSMA x CD3 T-cell engagers at the American Association for Cancer ResearchⓇ (AACR) 116th Annual Meeting, to be held April 25 to 30 at the McCormick Place Convention Center in Chicago, Illinois.\n\nDetails on AbCellera’s poster presentation at AACR are as follows:\n\nTitle: PSMA x CD3 T-cell engagers show preclinical efficacy for the treatment of prostate cancer\nAbstract Number: 6012\nSession: Therapeutic Antibodies, Including Engineered Antibodies 2\nDate and Time: Tuesday, April 29, from 2:00 p.m. to 5:00 p.m. CDT\nLocation: Section 35, Board 7\n\nAbout AbCellera’s T-Cell Engager Platform\n\nCD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding tumor targets and the CD3 protein on cancer-killing T cells at the same time. However, the development of T-cell engagers has been limited due to challenges with efficacy and safety. To address these challenges, AbCellera developed a T-cell engager platform that includes novel CD3-binding antibodies to expand the therapeutic window for this modality and costimulatory building blocks to enhance efficacy for difficult-to-treat cancers.\n\nAbout AbCellera Biologics Inc.\n\nAbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.\n\nAbCellera Forward-Looking Statements\n\nThis press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this...